Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspen Pharmacare Holdings's revenue per share for the
six
months ended in Jun. 2026 was $2.44.
Aspen Pharmacare Holdings's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $4.65.
Warning Sign:
Aspen Pharmacare Holdings Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Aspen Pharmacare Holdings was 2.80% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 4.60% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 6.10% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 2.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Aspen Pharmacare Holdings's Revenue per Share or its related term are showing as below:
APNHY'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.5 Med: 15.45 Max: 33.4
Current: 4.6
During the past 13 years, Aspen Pharmacare Holdings's highest 3-Year average Revenue Per Share Growth Rate was 33.40% per year. The lowest was -6.50% per year. And the median was 15.45% per year.
APNHY's 3-Year Revenue Growth Rate is ranked better than 53.26% of 905
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs APNHY: 4.60
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Aspen Pharmacare Holdings Revenue per Share Related Terms
Aspen Pharmacare Holdings Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APNHY vs ZTS, UTHR, VTRS: Revenue per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's PS Ratio falls into.
Aspen Pharmacare Holdings Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Aspen Pharmacare Holdings's Revenue Per Share for the fiscal year that ended in Jun. 2026 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $4.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspen Pharmacare Holdings (APNHY) has a Revenue per Share of $4.65 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Aspen Pharmacare Holdings and its competitors. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #423 out of 905 companies in the Drug Manufacturers industry, placing it in the top 46.7%.
Is Aspen Pharmacare Holdings' Revenue per Share too high?
Aspen Pharmacare Holdings' current Revenue per Share is $4.65. The Drug Manufacturers industry median Revenue per Share is 3.70. Aspen Pharmacare Holdings' value of $4.65 is 25.7% above this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #423 out of 905 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aspen Pharmacare Holdings has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Revenue per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #423 out of 905 companies for Revenue per Share. This puts Aspen Pharmacare Holdings in the upper half of its industry. The industry median Revenue per Share is 3.70. Aspen Pharmacare Holdings' value of $4.65 is 25.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.70, based on 905 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current Revenue per Share of $4.65 is 25.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Aspen Pharmacare Holdings and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current Revenue per Share is $4.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (APNHY) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.47, compared to a current price of $10.05 — trading 18.7% above its estimated fair value. The current Revenue per Share is $4.65 and 25.7% above the Drug Manufacturers industry median of 3.70. Aspen Pharmacare Holdings' overall GF Score™ is 69/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Aspen Pharmacare Holdings (APNHY), the current Revenue per Share is $4.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (APNHY) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be overvalued.
The current stock price of $10.05 is trading 18.7% above its estimated GF Value™ of $8.47.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Overvalued.
Key valuation signals for APNHY:
Revenue per Share: $4.65
GF Value™: $8.47 vs. price of $10.05 (18.7% above fair value)
Industry Position: 25.7% above the Drug Manufacturers median (#423 of 905)
No single metric tells the full story. See the APNHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
69GF Score
Get the complete analysis for APNHY
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APNHY has been successfully added to your 
